THU0111 Frequency and predictors of sustained remission in patients with early rheumatoid arthritis treated with conventional synthetic disease modifying drugs

2018
Background The management of patients with early rheumatoid arthritis (RA) should be aimed at reaching the target of disease remission as soon as possible. In order to prevent joint damage and disability, and eventually allow treatment withdrawal, the state of disease remission should be also maintained. Whilst point remission is frequently achieved in early RA, the sustainability of remission in clinical practice remains poorly investigated. Objectives To investigate the prevalence and predictors of sustained remission in patients with early RA treated with conventional synthetic disease anti-rheumatic drugs (csDMARDs). Methods We evaluated 533 RA patients from the Pavia early arthritis inception cohort not in remission at baseline with at least 24 months of follow-up. Patients had arthritis of short duration ( Results 287/533 (53.9%) patients achieved point DAS28 remission and 234/533 (43.9%) point SDAI remission. Independent predictors of point DAS28 remission were male gender (HR [95% CI] 1.84 [1.36–2.50]), shorter symptoms’ duration (HR [95% CI] 0.99 [0.98–0.99], a lower tender joint count at baseline (HR [95% CI] 0.97 [0.94–0.99]), better functional status (HR [95% CI] 0.74 [0.59–0.94]), absence of radiographic erosions (HR [95% CI] 1.52 [1.06–2.20]) and use of prednisone (HR [95% CI] 1.51 [1.36–1.74]). The same predictors were confirmed for point SDAI remission. Irrespective of the criterion, remission was maintained by only half of the patients at follow-up, resulting in sustained remission rates of 28% for DAS28% and 19% for SDAI in the entire cohort. At multivariate analysis, independent predictors of sustained remission according to either the DAS28 or the SDAI were lower time to achieve remission and deeper remission, whilst demographic factors, baseline disease activity and use of prednisone were not significant (figure 1). Using ROC curve analysis, the best discriminative ability for sustained remission were time to remission ≤4 months, DAS28 at remission ≤2.2 and SDAI at remission ≤1. Conclusions Despite early diagnosis and prompt institution of goal-steered treatment strategies with csDMARDs, only a minority of RA patients experience sustained remission. Remission is more likely to be maintained if the target is attained rapidly after treatment institution and if joint and systemic inflammation are effectively suppressed. Disclosure of Interest None declared
    • Correction
    • Source
    • Cite
    • Save
    0
    References
    0
    Citations
    NaN
    KQI
    []
    Baidu
    map